Research programme: small molecule neurogenic therapeutics - NeuralstemAlternative Names: NSI-144; NSI-150; NSI-158
Latest Information Update: 24 Oct 2012
At a glance
- Originator Neuralstem
- Class Small molecules
- Mechanism of Action Neurogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Major depressive disorder